TABLE 1.
Gastrointestinal cancers and relative HDAC6 inhibitors.
| Cancer | HDAC6 inhibitors | Substrate/pathway |
|---|---|---|
| Esophageal cancer | SiRNA | α-Tubulin and HSP90 |
| MiR-601 | — | |
| ACY1215 | G2/M arrest and apoptosis via miR-30d/PI3K/AKT/mTOR and ERK pathways | |
| GC | DTBP | Senescence |
| Mitotic catastrophe | ||
| TC24 | G2/M cell cycle arrest | |
| HIF-1α and VEGF | ||
| CRC | ACY-1215 | Caspase-3/poly (ADP ribose) polymerase/Bcl-2/pERK and pPKB |
| Programmed death ligand 1 | ||
| CHOP and ER stress | ||
| A452 + SAHA | γH2AX and Chk2 | |
| TSA + SAHA | Wnt transcription factor TCF7L2 | |
| Aceroside VIII + A452 | Acetylated α-tubulin | |
| Compound 12 | Cy987totoxic effects | |
| CRA-026440 | Acetylated histone and acetylated tubulin | |
| 23bb | α-Tubulin | |
| Compound 6 | Caspase and PARP | |
| C1A | KRAS | |
| Tubacin | CD133þ tumor-derived EVs | |
| MPT0G612 | Apoptosis | |
| Liver cancer | (E)-N-hydroxy-3-acry-lamide | — |
| miR-221 | JNK/c-Jun signaling | |
| Pancreatic cancer | Tubastatin A | — |
| CUDC-907 | c-Myc and Ki67 | |
| Cefoperazone sodium | — | |
| CCA | — | — |
pPKB, phosphorylated protein kinase B.